Society of Urologic Oncology (SUO)

The Society of Urologic Oncology (SUO) developed a clinical trials network in 2008. Created, owned, and operated by its members, the Society of Urological Oncology Clinical Trials Consortium (SUO-CTC) is a clinical research investigator network of over 340 members from more than 180 clinical sites in the US and Canada. This national alliance of leading academic and community-based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and maintains a cooperative relationship with the Society of Urologic Oncology. SUO-CTC pursues clinical trials, in concert with sponsors, to investigate therapeutic interventions which address urological cancers including, but not restricted to bladder cancer, prostate cancer and renal cancer. Together with industry, the SUO-CTC offers enhanced research options for ultimately delivering better quality of life to our patients. *

	Start	2008-01-01 existent
	Industry	oncology
	Industry 2	urological drug

	City	n. a.
		Address record changed: 2019-11-27

Basic data	Employees	n. a.

		* Document for »About Section«: Ferring Pharmaceuticals S.A.. (11/25/19). "Press Release: Ferring and Blackstone Life Sciences Invest over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients". Saint-Prex & Cambridge, MA.

		Record changed: 2023-06-26

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]